Stock Updates

How has Novo Nordisk A/S:(NYSE:NVO) performed recently?

Novo Nordisk A/S (NYSE: NVO) is a large market cap stock with a market cap of 94351.74. It is in the Drug Manufacturers – Other industry and sector Healthcare, with a current P/E of 21.83, a forward P/E of 18.83 and EPS of 2.12. At a stock price of 46.82 (1.39%) it has a dividend yield of 3.05%.

EPS growth for the last five years have been 22.40%, more recently this last year it has grown by 34.30%. The next year growth is going to be about 7.82% and more long-term 12.30% after five years. EPS growth quarter over quarter is 21.50%. Sales growth for the past five years have been 12.20% and sales growth quarter over quarter is 1.50%.

For performance, Novo Nordisk A/S the past week has seen a gain of -6.52%. For the last month performance for Novo Nordisk A/S is -15.83%. While the last quarter is -13.79% and half year, -2.77%. Finally for the year, performance is -15.98%.

The 52-week high for Novo Nordisk A/S, is at -18.47%, and for the 52-week low it comes to a value of 4.19%. The 20-day simple moving average is -12.05% and -12.48% for the 200-day simple moving average.

Volatility for the week is at 1.67%, and for the month it is 1.24%. Novo Nordisk A/S, has a target price of 57.

In terms of debt, long term debt/equity is 0, and for total debt/equity Novo Nordisk A/S has 0.01. The gross margin is 84.80%, while operating margin is 43.40%, the profit margin is 32.70%. The current ratio is 1.3 and the quick ratio is 0.9.

Insider ownership is at 26.40%, with instituitional ownership at 10.30%. Novo Nordisk A/S has a payout ratio of 45.20%. With the total shares outstanding coming to 2043.13. The shares float is 1356.68, with the float short at 0.16%, with short ratio coming to 1.19.

In terms of returns, the return on assets see Novo Nordisk A/S, get 41.50%, with its returns on investment at 85.00%. Return on equity is 84.90%. So will the investors see the target price of 57, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Mark Hines

Leave a Comment